...
首页> 外文期刊>RSC Advances >Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products
【24h】

Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products

机译:FFA4和FFA1的无标记细胞表型研究以及自然产品的FFA4新型激动剂的发现

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In this article, pharmacological studies of the free fatty acid receptor (FFA) 4 and FFA1 were conducted in transfected CHO cells (FFA4&FFA1) and HT29 cells with application of a label-free dynamic mass redistribution (DMR) assay. Commercially available compounds including -linolenic acid (ALA), GW9508, TUG891, GSK137647A, TAK875, MEDICA16, AH7614 and GW1100, were used to validate the assay; real-time tracing of ligand-induced cell responses elucidated pharmacological properties of ligand-receptor interactions. A pool of 140 natural compounds was screened using the CHO-FFA4 cells. Three new FFA4 agonists with novel skeletons were discovered and they were dihydrotanshinone, emodin and acetylshikonin (EC50 values were 32.88, 38.18 and 10.17 M, respectively). Ligand selectivity was compared between FFA4 and FFA1; dihydrotanshinone and emodin displayed FFA4 selectivity, while acetylshikonin shared FFA1 and FFA4 agonist activities with EC50 values comparable to the endogenous ligand ALA. The three novel FFA4 agonists provide a promising chemical starting point for identification and optimization of drugs used for treating metabolic and inflammatory diseases. Besides, this work will help to explain the mechanism of actions of natural products.
机译:在本文中,在转染的CHO细胞(FFA4和FFA1)和HT29细胞中进行游离脂肪酸受体(FFA)4和FFA1的药理研究,其施用无标记的动态分量再分布(DMR)测定。使用市售的化合物,包括-Linlenic acid酸(ALA),GW9508,Tug891,GSK137647A,TAK875,MEDICA16,AH7614和GW1100用于验证测定;配体诱导的细胞应答的实时追踪阐明了配体 - 受体相互作用的药理学性质。使用CHO-FFA4细胞筛选140个天然化合物的池。发现了三种新的FFA4激动剂,具有新骨骼的新骨髓,它们是Dihydrotanshinone,乙酰肾上腺素(EC50值分别为32.88,38.18和10.17 m)。在FFA4和FFA1之间比较配体选择性; Dihydrotanshinone和大蛋白显示FFA4选择性,而乙酰胆甙共享FFA1和FFA4激动剂活动,EC50值与内源性配体ALA相当。三种新型FFA4激动剂提供了有希望的化学出发点,用于鉴定和优化用于治疗代谢和炎症性疾病的药物。此外,这项工作将有助于解释天然产品的行为机制。

著录项

  • 来源
    《RSC Advances》 |2019年第26期|共11页
  • 作者单位

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    DICP CMC Innovat Inst Med Taizhou 225300 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    Dalian Med Univ Liaoning Prov Core Lab Med Mol Biol Dalian 116044 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

    Chinese Acad Sci Dalian Inst Chem Phys Key Lab Separat Sci Analyt Chem Dalian 116023 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号